Mazindol – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Mazindol is a tetracyclic compound that inhibits norepinephrine reuptake (NET, with potency around 30 nM) plus weaker dopamine and serotonin reuptake. Critically, it is a true reuptake inhibitor, not a transporter-reversing releaser like amphetamine. FDA-approved in 1973 (Sanorex, Mazanor) as a short-term obesity drug, withdrawn from the US market in 2001 when the appetite-suppressant category collapsed. Recently NLS Pharmaceutics has revived it as a controlled-release formulation for narcolepsy with cataplexy and ADHD. Useful as a non-amphetamine reference NRI/DRI in pharmacology research, particularly for investigators who want monoamine-uptake inhibition without the release pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A half-century-old withdrawn anorectic with modest renewed interest in narcolepsy and ADHD

Look, mazindol has a story, but it’s mostly a story about what used to matter. FDA approved in 1973 as Sanorex and Mazanor, withdrawn from the US market in 2001 when the anorectic category got picked apart by post-fen-phen regulatory scrutiny. What remained is a tetracyclic scaffold with a genuinely interesting pharmacological property: it inhibits NET (Ki around 30 nM), hits DAT weakly, and touches SERT even more weakly, but it does all of this as a true reuptake inhibitor rather than a transporter-reverser like the amphetamines. That distinction matters mechanistically. Amphetamines force transporters into reverse gear; mazindol just sits in them. The behavioral and abuse-liability profiles diverge from that mechanistic difference, and thats the main reason it remains a useful reference compound for investigators who need to parse reuptake inhibition from release in catecholamine pharmacology studies.

The contemporary angle is NLS Pharmaceutics, a Swiss company that has been running controlled-release mazindol through trials for narcolepsy with cataplexy and ADHD. Their phase 2 and phase 3 work represents the most credible recent human data for this compound. The narcolepsy signal is real enough that it generated legitimate clinical interest, and the non-amphetamine, non-releasing profile is exactly what that indication needs from a regulatory and tolerability standpoint. So it’s not dead. But we have to be honest about what the ceiling is here: the mechanism is NE/DA reuptake inhibition in 2024, a category that already has atomoxetine, methylphenidate, viloxazine, and modafinil competing for attention. Mazindol doesn’t dominate any of those comparisons on mechanism promise or differentiation.

What we actually like about it is the bench tool angle. As a high-affinity NET ligand with known transporter selectivity, it remains a credible probe for investigators studying sympathomimetic vs. releasing-agent effects, or for studies that need a non-releasing NRI control arm. It’s not exciting in the way that a triple agonist or a mitochondrial peptide is exciting, but it earns its slot in a research library as a reference compound with a long pharmacological history and a clear mechanistic profile.

What we don’t like: the evidence base is aging and fragmented. Historical obesity data is mostly low-quality by modern standards. The NLS trials are the most current and rigorous data, but they’re narrow in indication scope. Replication outside that consortium is thin. The compound is Schedule IV, which adds procurement overhead for any lab that wants to work with it seriously. For most research programs, atomoxetine or methylphenidate will answer the same questions with less regulatory friction. Mazindol earns a place as a niche tool, not as a priority target.

Novelty: 25
Mechanism promise: 35
In-category differentiation: 35
Evidence quality: 50
Translational signal: 52
Research bench value: 45

Rationale Mazindol is a 1973-approved, 2001-withdrawn Schedule IV anorectic. The NLS Pharmaceutics controlled-release narcolepsy program gives it some contemporary signal, but the compound itself is old, the mechanism (NRI/weak DRI) is mechanistically unremarkable by today’s standards, and differentiation from existing approved options is thin. Schedule IV cap (75) does not bind at the calculated score of 39.

Tetracyclic norepinephrine reuptake inhibitor (anorectic)

A tetracyclic NRI with weak DAT and SERT activity; a discontinued anorectic agent investigated for narcolepsy and ADHD.

Abstract

Mazindol ((R/S)-5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; CAS 22232-71-9; molecular formula C16H13ClN2O; molecular weight 284.74) is a tetracyclic norepinephrine reuptake inhibitor with secondary dopamine transporter inhibition, originally approved by the FDA in 1973 (Sanorex, Mazanor) for short-term obesity treatment. Withdrawn from the US market in 2001. Mechanism: NET inhibition (Ki approximately 30 nM) with weak DAT and SERT inhibition; distinct from amphetamines by being a true reuptake inhibitor rather than a transporter-reversing releaser. Plasma half-life is approximately 10 hours. Recent development by NLS Pharmaceutics has investigated mazindol controlled-release for narcolepsy with cataplexy and ADHD. Used as a non-amphetamine reference NRI/DRI compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-382Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.